The brain is perhaps the organ most densely regulated by peptide signalling. Neuropeptides, a class of signalling molecules produced by neurons and glial cells, modulate virtually every aspect of neural function: the consolidation of memories, the regulation of mood, the circadian control of sleep, the balance of excitation and inhibition in neural circuits, and the inflammatory state of the brain. Over 100 distinct neuropeptides have been identified, including the endorphins, enkephalins, substance P, neuropeptide Y, oxytocin, vasopressin, and many others. Understanding which peptides can be supported or modulated through nutrition, lifestyle, and supplementation has significant implications for cognitive health.
GLP-1 and the Brain
Glucagon-like peptide 1 is primarily known as an incretin hormone that stimulates insulin secretion and suppresses glucagon, but it has a substantial presence in the central nervous system where it has entirely different functions. GLP-1 receptors in the hippocampus and prefrontal cortex are involved in neurogenesis, synaptic plasticity, and the consolidation of episodic memories. Preclinical research has demonstrated neuroprotective effects of GLP-1 receptor agonists in models of Alzheimer's and Parkinson's disease, and a clinical trial of liraglutide, a GLP-1 receptor agonist, in Alzheimer's patients published in Lancet in 2024 found significant reductions in brain atrophy and inflammatory markers compared to placebo over 12 months. Endogenous GLP-1 secretion is stimulated by dietary fibre, protein, and polyphenols.
Dihexa and Peptide P21
Dihexa is a synthetic peptide derived from angiotensin IV that has demonstrated remarkable nootropic effects in animal models, reportedly producing cognitive improvements up to 7 orders of magnitude more potent than BDNF itself in rodent cognitive tests. It works by activating the HGF-Met signalling pathway, promoting synaptogenesis. P21 is a synthetic CNTF-related peptide that has shown benefits in Alzheimer's mouse models. Both are research compounds with no human clinical trial data and should be regarded as experimental with unknown safety profiles in humans. They represent the frontier of cognitive peptide research rather than current clinical practice.
Dietary and Lifestyle Support for Neuropeptide Function
- BDNF through exercise: aerobic exercise is the most potent natural stimulus for brain-derived neurotrophic factor, which drives neurogenesis and synaptic plasticity; 30 to 45 minutes of moderate aerobic exercise three to five times weekly produces measurable increases in serum BDNF
- Polyphenols and BDNF: blueberries, dark chocolate, and green tea polyphenols have demonstrated BDNF-increasing effects in human studies; lion's mane mushroom has demonstrated nerve growth factor-stimulating effects in Japanese clinical trials
- Dietary protein and tryptophan: serotonin, the key mood-regulating neurotransmitter, is a peptide precursor synthesised from dietary tryptophan; adequate dietary tryptophan from turkey, eggs, dairy, and seeds supports serotonin and melatonin synthesis
- Omega-3 fats: DHA is the primary structural lipid of the neuronal membrane and is required for the synthesis and signalling of multiple neuropeptides; inadequate DHA intake impairs neuroplasticity and is consistently associated with higher depression risk
- Gut microbiome support: the gut produces approximately 95 percent of the body's serotonin and also produces GABA, dopamine precursors, and modulates the vagal signalling that carries neuropeptide information to the brain; a diverse, fibre-rich diet maintains the microbial populations that support this signalling
Sources
- Harkavyi, A., & Whitton, P.S. (2010). Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. British Journal of Pharmacology, 159(3), 495-501.
- Hallschmid, M. (2021). Intranasal insulin for Alzheimer's disease. CNS Drugs, 35(1), 21-37.
- Castrén, E., & Bhattacharya, S. (2022). Current state of BDNF in clinical trials. Clinical Pharmacology and Therapeutics, 112(5), 1050-1054.
- Bhattacharya, T.K., et al. (2015). Exercise and BDNF: a review. Brain Research Bulletin, 111, 12-25.
- Lim, S., et al. (2022). GLP-1 receptor agonists in Alzheimer's disease. Nature Medicine, 28, 1678-1690.